|
1
|
Glover DM, Hagan IM and Tavares AA:
Polo-like kinases: A team that plays throughout mitosis. Genes Dev.
12:3777–3787. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andrysik Z, Bernstein WZ, Deng L, Myer DL,
Li YQ, Tischfield JA, Stambrook PJ and el Bahassi M: The novel
mouse polo-like kinase 5 responds to DNA damage and localizes in
the nucleolus. Nucleic Acids Res. 38:2931–2943. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Cárcer G, Escobar B, Higuero AM, García
L, Ansón A, Pérez G, Mollejo M, Manning G, Meléndez B,
Abad-Rodríguez J and Malumbres M: Plk5, a polo box domain-only
protein with specific roles in neuron differentiation and
glioblastoma suppression. Mol Cell Biol. 31:1225–1239. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Cárcer G, Manning G and Malumbres M:
From Plk1 to Plk5: Functional evolution of polo-like kinases. Cell
Cycle. 10:2255–2262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seeburg DP, Pak D and Sheng M: Polo-like
kinases in the nervous system. Oncogene. 24:292–298. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hansen DV, Loktev AV, Ban KH and Jackson
PK: Plk1 regulates activation of the anaphase promoting complex by
phosphorylating and triggering SCFbetaTrCP-dependent destruction of
the APC Inhibitor Emi1. Mol Biol Cell. 15:5623–5634. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Golsteyn RM, Mundt KE, Fry AM and Nigg EA:
Cell cycle regulation of the activity and subcellular localization
of Plk1, a human protein kinase implicated in mitotic spindle
function. J Cell Biol. 129:1617–1628. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lane HA and Nigg EA: Antibody
microinjection reveals an essential role for human polo-like kinase
1 (Plk1) in the functional maturation of mitotic centrosomes. J
Cell Biol. 135:1701–1713. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petronczki M, Glotzer M, Kraut N and
Peters JM: Polo-like kinase 1 triggers the initiation of
cytokinesis in human cells by promoting recruitment of the RhoGEF
Ect2 to the central spindle. Dev Cell. 12:713–725. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lowery DM, Lim D and Yaffe MB: Structure
and function of Polo-like kinases. Oncogene. 24:248–259. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Vugt MA and Medema RH: Getting in and
out of mitosis with Polo-like kinase-1. Oncogene. 24:2844–2859.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takai N, Hamanaka R, Yoshimatsu J and
Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene.
24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takaki T, Trenz K, Costanzo V and
Petronczki M: Polo-like kinase 1 reaches beyond
mitosis-cytokinesis, DNA damage response, and development. Curr
Opin Cell Biol. 20:650–660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
el Bahassi M: Polo-like kinases and DNA
damage checkpoint: Beyond the traditional mitotic functions. Exp
Biol Med (Maywood). 236:648–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kotani S, Tugendreich S, Fujii M,
Jorgensen PM, Watanabe N, Hoog C, Hieter P and Todokoro K: PKA and
MPF-activated polo-like kinase regulate anaphase-promoting complex
activity and mitosis progression. Mol Cell. 1:371–380. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nigg EA: Mitotic kinases as regulators of
cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartek J and Lukas J: DNA damage
checkpoints: From initiation to recovery or adaptation. Curr Opin
Cell Biol. 19:238–245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macůrek L, Lindqvist A, Lim D, Lampson MA,
Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB and Medema
RH: Polo-like kinase-1 is activated by aurora A to promote
checkpoint recovery. Nature. 455:119–123. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seki A, Coppinger JA, Jang CY, Yates JR
and Fang G: Bora and the kinase Aurora A cooperatively activate the
kinase Plk1 and control mitotic entry. Science. 320:1655–1658.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Vugt MA, Brás A and Medema RH:
Polo-like kinase-1 controls recovery from a G2 DNA damage-induced
arrest in mammalian cells. Mol Cell. 15:799–811. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mamely I, van Vugt MA, Smits VA, Semple
JI, Lemmens B, Perrakis A, Medema RH and Freire R: Polo-like
kinase-1 controls proteasome-dependent degradation of Claspin
during checkpoint recovery. Curr Biol. 16:1950–1955. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Holtrich U, Wolf G, Bräuninger A, Karn T,
Böhme B, Rübsamen-Waigmann H and Strebhardt K: Induction and
down-regulation of PLK, a human serine/threonine kinase expressed
in proliferating cells and tumors. Proc Natl Acad Sci USA.
91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jang YJ, Kim YS and Kim WH: Oncogenic
effect of Polo-like kinase 1 expression in human gastric
carcinomas. Int J Oncol. 29:589–594. 2006.PubMed/NCBI
|
|
24
|
Takahashi T, Sano B, Nagata T, Kato H,
Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like
kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He ZL, Zheng H, Lin H, Miao XY and Zhong
DW: Overexpression of polo-like kinase1 predicts a poor prognosis
in hepatocellular carcinoma patients. World J Gastroenterol.
15:4177–4182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weichert W, Schmidt M, Gekeler V, Denkert
C, Stephan C, Jung K, Loening S, Dietel M and Kristiansen G:
Polo-like kinase 1 is overexpressed in prostate cancer and linked
to higher tumor grades. Prostate. 60:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weichert W, Kristiansen G, Winzer KJ,
Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M and
Denkert C: Polo-like kinase isoforms in breast cancer: Expression
patterns and prognostic implications. Virchows Arch. 446:442–450.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
King SI, Purdie CA, Bray SE, Quinlan PR,
Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection
of Polo-like kinase-1 (PLK1) in primary breast cancer is associated
with TP53 mutation and poor clinical outcome. Breast Cancer Res.
14:R402012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weichert W, Denkert C, Schmidt M, Gekeler
V, Wolf G, Köbel M, Dietel M and Hauptmann S: Polo-like kinase
isoform expression is a prognostic factor in ovarian carcinoma. Br
J Cancer. 90:815–821. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB,
Pan X and Yin YM: Overexpression of polo-like kinase 1 and its
clinical significance in human non-small cell lung cancer. Int J
Biochem Cell Biol. 44:200–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weiß L and Efferth T: Polo-like kinase 1
as target for cancer therapy. Exp Hematol Oncol. 1:382012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yim H: Current clinical trials with
polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs.
24:999–1006. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamanaka R, Maloid S, Smith MR, O'Connell
CD, Longo DL and Ferris DK: Cloning and characterization of human
and murine homologues of the Drosophila polo
serine-threonine kinase. Cell Growth Differ. 5:249–257.
1994.PubMed/NCBI
|
|
34
|
Bloom HJ and Richardson WW: Histological
grading and prognosis in breast cancer; a study of 1409 cases of
which 359 have been followed for 15 years. Br J Cancer. 11:359–377.
1957. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Hoboken, NJ: 2009.
|
|
36
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Halon A, Donizy P, Surowiak P and
Matkowski R: ERM/Rho protein expression in ductal breast cancer: A
15 year follow-up. Cell Oncol (Dordr). 36:181–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fitzgibbons PL1, Page DL, Weaver D, Thor
AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly
JL, et al: Prognostic factors in breast cancer. College of American
Pathologists Consensus Statement 1999. Arch Pathol Lab Med.
124:966–978. 2000.PubMed/NCBI
|
|
39
|
Degenhardt Y and Lampkin T: Targeting
Polo-like kinase in cancer therapy. Clin Cancer Res. 16:384–389.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
41
|
Tirkkonen M, Tanner M, Karhu R,
Kallioniemi A, Isola J and Kallioniemi OP: Molecular cytogenetics
of primary breast cancer by CGH. Genes Chromosomes Cancer.
21:177–184. 1998. View Article : Google Scholar : PubMed/NCBI
|
